Abstract: A perspective is offered on the recent development of Src-homology 2 (SH2) antagonists of Src, Grb2 and ZAP-70. Inhibiting Src SH2 is believed to be a potentially attractive way of regulating bone resorption. Grb2 SH2 has been shown to be an important component of the mitogenic ras pathway; and thus might be of utility in cancer research. ZAP-70 is a tyrosine kinase that is expressed solely in T-cells and natural killer cells. Since inhibition of the tandem SH2 domains of ZAP-70 has been shown to block T-cell proliferation, antagonists for this particular protein could have implications in immune suppression. The emphasis of the article is placed on the structure-based design, synthesis and biological activity of a number of newly reported SH2 antagonists in each of the three areas.
Introduction
these SH2 domains in essence must contain a very basic pocket in order to accommodate the phosphotyrosine and a lipophilic pocket in order to accomodate the X 3 group. In terms of intracellular functions, these SH2 domains play an important part in signal transduction by their ability to transmit signals [5] , to act as adaptors between receptors [6] or to regulate the kinase activity of a specific protein [7] . Therapeutic intervention by means of SH2 inhibition has now been recognized as a potentially attractive avenue [8] . With the recent availability of structural information on a number of these SH2-containing proteins [9] , the challenging process of designing potent and selective SH2 inhibitors has also become more rational and successful.
Mammalian cellular signal transduction is regulated by a vast array of specific protein tyrosine kinases and protein tyrosine phosphotases. The protein tyrosine kinases (PTKs) have recently witnessed a number of important breakthroughs in potency and selectivity; and have thus increasingly gained acceptance as attractive medicinal targets for a variety of therapeutic areas [1] . In cellular signal transduction, the phosphorylation state of various proteins is regulated not only by PTKs, but also by the opposing action of the protein tyrosine phosphatases (PTPs). To date, a large number of PTPs have been identified, and these also have been the subject of numerous investigations and reviews [2] .
In recent years, three particular SH2-containing targets have been the subject of intense research by a number of laboratories. Src SH2 is one of the first and most widely studied target in this particular field [10] . The growth receptor bound protein 2 (Grb2) is another SH2-containing target which has gained some recent attention in the area of cancer research [11, 12] . Last but not least is ZAP-70, a tyrosine kinase that is expressed solely in T-cells and natural killer cells. The importance of ZAP-70 in regulating T-cell functions has made this particular protein tyrosine kinase one of the more desirable medicinal target for immune suppression [13] . In this article, newly reported SH2 antagonists are reviewed. Since structural information is available for each of these three proteins, the focus is on the structure-based design and synthesis of highaffinity ligands. In situations where structure-activity relationship is discussed, attempts will be made to In addition to the PTKs and PTPs, the Srchomology 2 (SH2) domains also play a critical role in intracellular signal transduction by mediating a variety of protein-protein interactions. Numerous reviews are now available on the biological significance of SH2 domains in cellular signal transduction [3] . SH2 domains are relatively small, highly conserved protein units having about 100 amino acids that preferentially bind to specific tyrosine-phosphorylated proteins [4] . The preferred peptide sequence for SH2 domains is usually pTyr-X 1 -X 2 -X 3 (where X 1-3 are variable peptide units and X 3 is a peptide residue containing a lipophilic side chain such as Leu or Ile). To recognize specific tetrapeptide sequences of the type pTyr-X 1 -X 2 -X 3 , compare various analogs when they are being analyzed in the same SH2 binding assay. This is due to the fact that a number of different SH2 binding assays have now been reported. A few of these include a Biacore assay [14] , a fluorescence polarization (FP) binding assay [15] , an ELISA-type assay [16] , a surface plasmon resonance (SPR) assay [17] , a radiolabeled phosphonopeptide displacement assay [18] , and a scintillation proximity assay (SPA) [19] . An IC 50 for a particular SH2 inhibitor can vary greatly depending on the concentration of a given SH2 protein, and on the way a particular binding assay is set up.
native tetrapeptide sequence Ac-pYEEI-NH 2 is bound to the active site of Lck SH2. This model is constructed using the available coordinates from a known crystal structure. In Fig. (1 ) , the active site is represented in the form of a color coded solvent accessible surface [24] . The blue, red and yellow areas refer to the hydrogen bond donor, hydrogen bond acceptor, and hydrophobic atoms of the proteins respectively.
Src SH2 Inhibitors
In recent years, there have been a number of studies which indicate that the nonreceptor tyrosine kinase Src could play an important role in breast cancer [20] and in bone resorption [21] . This particular protein tyrosine kinase has previously been shown to contain an N-terminal unique domain followed by two Src homology domains (one SH2 and one SH3), a catalytic kinase domain, and a short C-terminal regulatory peptide sequence. The SH2 domain of Src could associate with specific phosphorylated proteins and thus enable a number of different intracellular signalling events to take places. Some of these processes include cell growth, proliferation, mitogenesis, and transformation [22] . In order to interrupt these intracellular signalling events, it is necessary to design agents that could selectively bind to the Src SH2 domain and thus prevent it from associating with the designated phosphorylated proteins.
Fig. (2).
Crystal structure of thiazole analog 12 bound to Lck SH2. Binding site is depicted in color coded solvent accessible surface. The blue, red, and yellow areas refer to the hydrogen bond acceptor, hydrogen bond donor, and hydrophobic atoms of the protein respectively.
A number of research groups have been using this structural information in order to design mimetics for this tetrapeptide sequence. A recent review has covered the design and biological activity of some important new leads in this area, namely the dipeptide derivative 1 and the benzamide derivative 2 [25] . Herein discussion is focused on some newly reported Src SH2 inhibitors [26] . (1) . Crystal structure of Ac-pYEEI-NH2 bound to Lck SH2. Binding site is depicted in color coded solvent accessible surface. The blue, red, and yellow areas refer to the hydrogen bond acceptor, hydrogen bond donor, and hydrophobic atoms of the protein respectively.
One of the more effective native ligands for the Src SH2 domain has been determined to be Ac-pYEEI-NH 2 . In a fluorescence polarization (FP) binding assay, this monophosphorylated tetrapeptide sequence has an IC 50 of 6 µM. The crystal structure of a high-affinity ligand (11-peptide residue) when it is bound to Src SH2 has been solved [23] . Fig. (1 ) depicts how the Examination of the structure of Ac-pYEEI-NH 2 when it is bound to Src SH2, Fig. (1 ) , reveals a large position. Furthermore, the synthesis of optically active derivatives of 4 is more convenient because of the availability of L-amino acids.
Scheme 1 outlines a racemic synthesis of a derivative of compound 3 . Commercially available 3-bromobenzaldehyde (5 ) was first condensed with EtMgCl and then subjected to a nickel-mediated coupling reaction with cyclohexylmethyl magnesium bromide in order to yield 6 . This alcohol could be manipulated in the usual fashion to afford the amine derivative 7 . Standard amide coupling procedure was used to couple 7 with BOC-Tyr(PO 3 Bn 2 )-OH. Compound 8 was obtained as a 1:1 mixture of diastereomers after deprotection and acetylation at the N-terminal. This compound had an IC 50 of 306 µM against Src SH2.
In contrast to the weak activity of compound 8 , the thiazole derivative 12 was substantially more active. Compound 12 was prepared according to the sequence outlined in Scheme 2. The thioamide derivative 9 was condensed with the bromoketone 10 and then cyclized under known conditions to afford the thiazole derivative 11. Upon removal of the BOC protecting group, the resulting amine could be coupled with Boc-Tyr(PO 3 Bn 2 )-OH. Standard conditions were used to unmask the phosphate group as well as to remove the side chain protecting group. The resulting compound 12, with an IC 50 of 26 µM against Src SH2, was only four fold less active than Ac-pYEEI-NH 2 .
Compound 12 was also potent enough to enable structural determination by X-ray crystallography and NMR. Fig. (2 ) depicts the crystal structure of 12 when it is bound to the active site of Lck SH2. hydrophobic surface at the pY+2 position. Furthermore, the second Glu residue does not appear to come into contact with this surface of the protein.
Structure-based design efforts at ARIAD have resulted in the initial proposal of compound 3 as a possible mimetic for Ac-pYEEI-NH 2 [27] . The benzene ring is used as a replacement for one of the glutamic acid residues, as well as a way to gain the extra hydrophobic contact with the protein at the pY+2 position. Concurrently, a related thiazole derivative 4 has also been proposed as a mimetic for Ac-pYEEI-NH 2 . With this design, the thiazole ring is supposed to be able to access the same hydrophobic surface at the pY+2 
Scheme 2.
With the availability of the co-crystal structure of 12 with Lck SH2, attention was then turned to the optimization at the pY+1 and pY+3 positions in order to improve binding affinity. In order to rapidly scan these positions, the thiazole ring was replaced with a 1,2,4-oxadiazole ring as in 15 [28] Previous studies have shown that these two ring systems appear to be interchangeable, at least against Src SH2. Compound 16, for example, with an IC 50 of 29 µM against Src SH2, is essentially equivalent to the thiazole derivative 12. The preparation of 1,2,4-oxadiazole analogs of the type 15 is straightforward and is outlined in Scheme 3. A desired BOC-protected amino acid was coupled with the amidoxime derivative NH 2 C=N(OH)R to afford 13. Cyclization to the 1,2,4-oxadiazole was carried out by refluxing 13 briefly in pyridine. The BOC-group was then removed with TFA and resulting amine 14 was coupled with the phosphorylated N-acetyl tyrosine derivative. Final treatment with TFA then afforded the corresponding phosphate derivative 15, which could be purified by reverse-phase HPLC. The preparation of 1,2,4-oxadiazole analogs was indeed more convenient than that of the thiazole derivatives because of the availability of the amidoximes (conveniently prepared by reacting nitriles with hydroxylamine hydrochloride in the presence of NaOH) [29] . The pY+3 position of 15 was scanned with a number of different groups while keeping the pY+1 position constant. Compound 17 quickly emerged as one of the more potent analogs in the series. Its IC 50 against Src SH2 of 7 µM was esentially equivalent to the native tetrapeptide sequence Ac-pYEEI-NH 2 . The carboxyl group at the pY+1 could also be replaced with a number of uncharged functional groups as in 18 and 19 with a minimal loss of Src SH2 binding affinity. SH2 domain of Src. A summary of their results is shown in Table 1 . Compound 20 was the control peptide, which had been designed previously to target the protein binding site. As expected, it had poor inhibitory activity (IC 50 = 1.6 mM). As apparent from the structure of compound 21, a SH2 recognition motif (Ac-pYEEIE-)was attached to the N-terminal of this control peptide. Since the actual atomic distance between the kinase domain and the Src SH2 domain in their active form is not known, the two binding sites are separated by a simple, flexible linker (Abu) n . As the linker region grew from 4 to 8 Abu peptide units (compounds 21-23), a significant increase in kinase inhibitory activity was observed. The kinase activity appeared to be optimal at 8 Abu peptide units and declined once the linker region grew to 10 or 12 Abu peptide units (compounds 24 and 25). These findings are indeed significant because up until recently Src SH2 inhibitors have been made solely as a way of blocking the assembly of Srcbased signalling events. With these bivalent inhibitors of Src, there is a possibility of blocking two different events. The first of which is the inhibition of SH2-A recent publication by Lawrence and coworkers [30] introduced an interesting application for Src SH2 inhibitors. Here, these researchers were focusing on the design of selective kinase inhibitors of Src. In their approach, they attempted to design compounds which would target the protein binding site of the kinase domain. However, previous work has shown that inhibitors which target the protein binding site usually tend to have poor inhibitory activity [31] . Lawrence and coworkers made one significant change in their design and that was to construct bivalent compounds that would bind to both the protein binding site and the sequence that could be recognized by Grb2 SH2 [34] . This tripeptide residue has an IC 50 of 8.64 µL against Grb2 SH2 in an ELISA-type assay. Using a preliminary model for the SH2 domain of Lck, Furet and coworkers then replaced the acetyl N-cap with a 3-aminobenzyloxycarbonyl group. The resulting compound 27 showed a substantial gain in Grb2 SH2 activity (IC 50 = 0.065 µL). This favorable effect could be rationalized by the π stacking interaction between the phenyl ring of the N-terminal group and the Arg α2 residue of the SH2 domain. The 3-amino group can also form an intramolecular hydrogen bond with the phosphate group and thus locks the N-terminal part of the peptide into the favorable stacking conformation [35] . mediated protein-protein interaction; and the second of which is the inhibition of catalytic activity of the kinase domain.
Further work from Novartis has resulted in the determination of the crystal structure of the Grb2 SH2 domain with the phosphopeptide Lys-Pro-Phe-pTyrVal-Asn-Val-NH 2 [36] . The phosphotyrosine group could presumably engage the pTyr pocket through a network of hydrogen bonds and charge-charge interactions in a manner similar to what had been observed in other SH2 domains. However, unlike other SH2-containing proteins, the peptide ligand does not bind to Grb2 in an extended conformation. Instead, the phosphotyrosine group, along with the three peptidic residues Val-Asn-Val, form a β-turn. As illustrated in Fig.  (3 ) , the β-turn conformation is formed by a direct hydrogen bond between the carbonyl oxygen of the phosphotyrosine residue and NH amide group of the pY+3 group. The Val group at the pY+1 position forms some weak hydrophobic contact with the protein. At the pY+2 position, the Asn residue in essence defines
Grb2 SH2 Inhibitors
In recent years, intracellular signalling events involving ras proteins have been directly implicated in many oncogenic processes. The SH2 domain of the Grb2 adaptor protein serves as a critical link between various growth factor receptors and ras proteins [32] . Any agents that could selectively bind to the SH2 domain of Grb2 might have the potential of preventing ras from triggering the MAP kinase cascade that is of absolute essential for cell growth and differentiation [33] .
Work carried out at Novartis has quickly established that Ac-pTyr-Ile-Asn-NH 2 (26) is the minimal peptide the specificity pocket because its carboxamide side chain forms three critical hydrogen bonds with the protein. One hydrogen bond exists between the carbonyl oxygen atom of the carboxamide side chain and the nitrogen atom of Lys 109 (βD-strand). The remaining two hydrogen bonds are formed between the nitrogen atom of the carboxamide side chain and the carbonyl oxygen atoms of Lys 109 (βD-strand) and Leu 120 (βE-strand). At the pY+3 position, the alkyl side chain of the Val group is directed toward an extended hydrophobic surface formed by the side chains of Leu-βD'1, Phe-βE3, and the hydrocarbon side chain of Lys-βD6.
The above structural information then allowed for a more rational approach to designing nonpeptidic and high-affinity Grb2 SH2 inhibitors. In one particular design, a (3-aminomethyl-phenyl)-urea group, as in 31, In order to obtain high-affinity ligands, researchers at Novartis exploited the hydrophobic surface that is present at the pY+3 position [38] . As mentioned earlier, this surface in essence is created by the side chains of Leu-βD'1, Phe-βE3, and the hydrocarbon side chain of Lys-βD6. Molecular modeling suggests that this surface could be accessed by installing hydrophobic groups at the C-terminal as in 33 and 34.
Compared with the reference tripeptide sequence 26, the dichloro analog 33 was about six-fold more active. However, the naphthyl derivative 34 was about 25-fold more active against Grb-2. Interestingly, compounds 33 and 34 were both made by solid-phase chemistry.
As illustrated in Scheme 5, Fmoc-Asp-OAll was first loaded onto the Rink amide MBHA resin (36) . Standard Fmoc amino acid coupling procedure was used to elaborate the N-terminal into compound 37. The Cterminal could then be elaborated by first removing the allyl protecting group. The resulting acid could then be coupled with a variety of amines. The phosphate group could be unmasked using TMSI and the resulting phosphate cleaved from the resin using 95% TFA. For effective Grb2-SH2 activity, primary amines should be used for the last step since the resulting NH amide will still allow for a β-turn to form.
could stabilize the 3 10 helical conformation as well as to enable van der Waals contacts with the PheβD5 and GlnβD3 groups of the protein [39] . In fact, with 1-amino-1-cyclohexanecarboxylic acid group at the pY+1 position, as in 35, a very substantial gain in Grb2 SH2 activity was observed (IC 50 = 0.047 µM).
With the availability of these high-affinity Grb2 SH2 ligands, Burke and coworkers then proceeded to investigate the cellular activity of these compounds. For effective cellular activity, the phosphate group would have to be replaced with a phosphataseresistant and membrane-permeable functional group. 
Scheme 6.
Burke and coworkers employed standard solution phase chemistry in order to prepare intermediate 49 (Scheme 6). This intermediate, of course, contained the key amine component of high-affinity Grb2-SH2 ligands previously identified by Novartis. As shown in Scheme 6, the naphthylpropylamine 47 was condensed with BOC-Asn-OSu. The BOC protecting group was removed and the resulting amine 48 was coupled to N-BOC-1-amino-1-cyclohexanecarboxylic acid. Upon removal of the BOC-protecting group, the resulting amine 49 could be coupled with a variety of phosphotyrosine mimetics and then deprotected appropriately.
for the F 2 cmF analog). This increase in binding affinity could be due to the extra hydrogen bond contact with the Arg67 residue. Compounds 53-55 represented some of the most active nonphosphate-containing inhibitors of Grb2-SH2 that had been disclosed to date. They were also rather interesting because they showed micromolar inhibitory activity in an intact cell assay which measured the association of endogenous Grb2 with its cognate p185 erbB-2 ligand. The observation that compounds 53-55 were membranepermeable without the need of prodrug derivatization was very significant. Furthermore, Burke and coworkers have also found that the Pmp group, as in 56, was a good replacement for the phosphate group in the area of Grb2 SH2 inhibition. Compound 56, unexpectedly, had the same binding affinity as the F 2 Pmp analog 50. Previous work in Src SH2 work had shown that a Pmp group was not usually a good replacement for the phosphate group. It is not clear at this point why this particular phosphonate derivative would work so well against Grb2-SH2 domain. When the N-cap was replaced with an oxalyl group as in 57, another two-fold increase in affinity was observed. Compound 57 also had good membrane permeability; and it possessed submicromolar activity in an intact cell assay which For the Grb2-SH2 work, Burke and coworkers have found that the F 2 Pmp analog 51 (IC 50 = 0.08 µM, SPR binding assay) was essentially equivalent to the phosphate derivative 35 (IC 50 = 0.047 µM) [47] . When the carboxylate-based tyrosine mimic 46 was used, as in 52, a rather substantial loss of binding affinity was observed (IC 50 = 6.7 µM). However, a five-fold gain in binding affinity was observed when an oxalyl group was used as the N-cap (compound 53, IC 50 = 1.3 µM). A similar gain in binding affinity was also observed when the oxalyl group was attached to the N-cap of the cmF and F 2 cmF derivatives (compounds 54 and 55 respectively IC 50 = 0.6 µM for the cmF and IC 50 = 2 µM measured the association of endogenous Grb2 with its cognate p185 erbB-2 ligand. Shortly after Burke's report regarding the potency of Pmp analogs in Grb2 SH2, researchers at Novartis have also confirmed a similar finding [48] . In a systematic study, a variety of substituted indole derivatives were used to explore the hydrophobic surface formed by the side chains of Leu-βD'1, Phe-βE3, and the hydrocarbon side chain of Lys-βD6. This hydrophobic surface was actually the same surface that had been accessed by the naphthyl group in compounds 51-57. What emerged out this work was a series of small molecules with an unprecended affinity toward Grb2 SH2 domain. Also of particular interest to many researchers in the area of signal transduction is the fact that all of these potent Grb2 SH2 inhibitors do not contain the phosphate moiety. Instead, a phosphataseresistant 4-(phosphonomethyl)phenylalanine (Pmp) group was present in all of the subnanomolar compounds. The synthesis of these Pmp analogs was As shown in Table 2 , compound 61, one of the more potent Grb2 SH2 inhibitors, had an IC 50 of 1.2 nM in an ELISA-type assay. Substitution with a methyl group at either the C-2 or C-3 resulted in a substantial loss of Grb2 SH2 activity. Modeling suggested that substitution at either the C-2 or C-3 would not be favorable because of possible steric hindrance at this particular position. Substitution at the C-5 position with Me and OH resulted in a nice gain in Grb2 SH2 acitivity. Compounds 64 and 65 were both subnanomolar Grb2 SH2 inhibitors. Interestingly, a chloro substitution at the C-5 position, as in 66, resulted in a large loss of binding affinity. The indolyl group was installed in order to exploit the hydrophobic contact with the side chain residues of Lys βD6 and Leu βD'1 of the Grb2 SH2 domain. Since this interaction, is by nature, a CH/π interaction between the aromatic ring of the indole and the alkyl groups of the side chains, electron enrichment of the aromatic system would result in an increase in binding affinity. So far, the best Grb2 SH2 inhibitors in this series are N-alkylated. A free NH indole derivative, as in 67, resulted in a substantial loss of binding affinity. Some of this binding affinity could, however, be regained by methylation this position as in 68.
resistant Grb-2 SH2 antagonists. Since some of these Grb2 inhibitors have now been shown to be membrane-permeable, it is of particular interest to see in the near future how these compounds would behave in a functional cellular assay.
ZAP-70 SH2 Inhibitors
A number of studies have recently shown the importance of the protein tyrosine kinase ZAP-70 in regulating T-cell functions. In ZAP-70 knockout mice or in humans with disrupted ZAP-70, T-cell function is essentially absent leading to a severely compromised immune response [49] . The activation of the tyrosine kinase ZAP-70 is dependent on a number of events; one of which involves the initial recognition of the T-cell From the above discussion, it is evident that substantial progress has been made in the design and synthesis of highly potent, selective and phosphatase- antigen receptor (TCR) with a specific antigen. This process, in turn, activates the Src-family tyrosine kinase Lck [50] . Lck is critical for the phosphorylation of specific tyrosine residues within the ζ-chains of the immunoreceptor tyrosine activation motifs (ITAMs) [51] . The tyrosine kinase ZAP-70 then associates with this doubly-phosphorylated ζ-ITAM through its tandem Srchomology 2 (SH2) domains [52] . The catalytic activation of ZAP-70 kinase and other downstream signalling events are dependent on this association between the ζ-ITAM and the two SH2 domains [53] . Thus, any agents which could selectively bind to either of these SH2 domains of ZAP-70 would potentially be of utility in immune suppression.
such as Ac-pYDVL-NH 2 and Ac-pYNEL-NH 2 , which could engage only a single SH2 domain, tend to bind poorly to the tandem SH2 domains of ZAP-70 (Table 3 , IC 50 = 300-500 µM). This is in sharp contrast with other SH2-containing proteins such as Src SH2 and Grb2 SH2 (Table 3 and previous discussion) where tetrapeptides usually bind with high affinity. Note that while the ζ-1-ITAM peptide is highly selective over Src SH2, its selectivity over Syk is only modest (about 10-fold). ZAP-70 and Syk belong to the same family of tyrosine kinases. Both of these kinases contain two tandem SH2 domains [55] . Previous work has shown that it is difficult to achieve selectivity between these two SH2-containing proteins even with large peptide sequences [56] . Whereas ZAP-70 is expressed only in T-cells and natural killer cells [57] , Syk is expressed in B cells, mast cells, polymorphonuclear leukocytes, platelets, macrophages and immature T cells [58] . In designing ZAP-70 SH2 antagonists, a high level of selectivity over Syk is therefore highly desirable.
The two SH2 domains of ZAP-70, appropriately labeled N and C-terminal ZAP, are joined by an interegion consisting of a 65-amino acid residue. Cterminal to the tandem SH2 domains is another amino acid sequence and a catalytic kinase domain. The crystal structure of the tandem SH2 domains of ZAP-70, when associated with a doubly phosphorylated peptide deriving from the ζ-ITAM unit (Ac-NQLpYNELNLGRREE-pYDVLD-NH 2 ) has recently been solved [54] . As shown in Fig. (4 ) , this 19-peptide residue (also referred to as the ζ-1-ITAM peptide) makes critical contacts with the protein via its two phosphotyrosine residues and its two lipophilic pY+3 groups (Leu residues). Even though the ζ-1-ITAM peptide binds in an extended configuration, it has a very high affinity toward the SH2 domains of ZAP-70 (IC 50 = 0.038 µM, fluorescent polarization binding assay, Table 3 ). Its actual Kd against ZAP-70 has been determined to be around 1-2 nM. This is perhaps due to the favorable entropic factors of engaging the two tandem SH2 domains. Shorter peptide sequences In contrast to the large number of studies that have been published in Src SH2 and Grb2 SH2, thus far there have been only a few reports on ZAP-70 SH2 inhibitors. Researchers from Novartis reported the first series of ZAP-70 SH2 inhibitors (compounds 69-72) in late 1997 [59] . Compounds 69 and 70 were designed as mimetics of the bidentate ζ-ITAM peptide. Both compounds were reported to be reasonably potent ZAP-70 SH2 inhibitors, as determined by the Biacore method. The monodentate compounds 71 and 72 were less active presumably because of the lack of favorable entropic factors in engaging the tandem SH2 domains of ZAP-70. Since compounds 69-72 contained non-hydrolyzable phosphate mimics, they reportedly also had cellular activity in a Jurkat T cell assay which measured the decrease in IL-2 production. Other than the reported ZAP-70 SH2 binding activity and T-cell activity, selectivity data for other SH2-containing proteins were not disclosed.
Shortly afterward, researchers from Novartis also disclosed a series of peptoids as ZAP-70 SH2 inhibitors [60] . Using standard solid-phase chemistries [61] , a small library of 27 single pure compounds was made. Peptoid 73 was identified as the most active one (IC 50 = 25 µM, Biacore method). When compared with the high-affinity ζ-1-ITAM peptide, compound 73 was about 800-fold less active. This compound was also selective over Lck and Grb2 SH2 domains. However, since this compound lacked the entropically favorable bidentate effect, it was apparently not potent enough to warrent further cellular studies.
Our laboratory has recently disclosed a series of low molecular weight, potent and selective SH2 inhibitors of ZAP-70 [62] . At the time of disclosure, this series of compounds represented some of the most selective ZAP-70 SH2 inhibitors. In terms of potency, some of the best compounds in the series were 200 to 400-fold more potent than the native tetrapeptide sequences.
number of commercially available nitriles. As shown in Table 4 , the para-Cl group as in 74c was better than a para-Me group. When the Cl group was moved to the meta position as in 74d, a decrease in binding affinity toward ZAP-70 was observed. However, ZAP-70 activity could be regained by using a m,p-Cl 2 disubstiution pattern as in 74e. An ortho substitution as in 74f and 74g, was not favorable and resulted in a substantial loss of ZAP-70 activity. The m,pdisubstitution pattern could be mimicked with a 2-naphthlene group, as in 74i. The 1-naphthalene substitution pattern (74h), however, was not as favorable.
Our initial ZAP-70 SH2 hits actually came out from the Src SH2 work. As discussed earlier in this review article, the 1,2,4-oxadiazole scaffold 15 was identified as a good mimetic for the monophosphorylated tetrapeptide sequence pYX 1 X 2 X 3 found in many SH2-containing targets. In our work, we routinely screened our Src SH2 hits against a variety of SH2 containing proteins such as ZAP-70 and Syk. Compound 74a , prepared from L-glutamine with a simple benzyl group at the pY+3 position, was identified as one of the more active Src SH2 inhibitors. It also displayed little affinity toward ZAP-70 and Syk. However, we noticed that when the pY+3 group became slightly larger as in 74b that the binding affinity toward Src decreased somewhat (Table 4) . At the same time, a substantial gain in ZAP-70 SH2 binding was observed. The selectivity over Syk was also unusual. We therefore decided to explore this series further to see if we could increase both the binding affinity and selectivity of this series toward ZAP-70.
With this small collection of favorable pY+3 groups, we began to scan the pY+1 position. From previous work with Src SH2 inhibitors, 10 we knew that a simple Me group at the pY+1 position could be quite effective. Thus, when L-alanine was replaced as the starting amino acid, the resulting 1,2,4-oxadiazole analogs showed roughly a two-fold increase in binding affinity (Table 5 , compounds 75a-j). Essentially the same SAR that was observed in analogs deriving from Lglutamine was observed here. Namely, a parasusbtitution (whether Cl or CF 3 ) on a benzyl group at the pY+3 was better than the meta-susbtitution (compounds 75b-c and 75f-g ). At the para substitution, the following order of activity was Keeping L-glutamine as the starting amino acids, we continued to scan the pY+3 position with a small observed I > Br = CF 3 > Cl > Me > F. Note that even though Br was comparable to CF 3 in ZAP-70 activity, the later group showed better selectivity over Src. As observed previously with analogs deriving from Lglutamine, the m,p-Cl 2 susbtitution was favorable; and the resulting compound 75d showed comparable ZAP-70 activity to the 2-naphthalene derivative 75e.
In the absence of an X-ray crystal structure, molecular modeling was used in order to predict the binding modes of these compounds. Fig. (5 ) and Fig.  (6 ) show how compound 75e could be positioned in the active site at the C-terminal and N-terminal ZAP respectively. At the C-terminal ZAP [ Fig. (5 ) ], the phosphotyrosine pocket is formed by three Arg groups. One of these Arg could presumably interact simultaneously with the phenyl ring of the pTyr as well as with the carbonyl group of the acetyl N-cap. At the pY+1 position, the NH amide makes a direct hydrogen bond to the carbonyl group of the backbone His. The 1,2,4-oxadiazole ring forms a spacer which directs the 2-naphthalene moiety deep into the pY+3 pocket. In addition, the oxygen atom of the 1,2,4-oxadiazole ring also forms a water-mediated hydrogen bond with the Leu group of the protein. At the N-terminal ZAP [ Fig.  (6 ) ], the region between the pY+1 and pY+2 is restricted by the presence of a backbone proline residue. The oxygen atom of the 1,2,4-oxadiazole ring therefore does not form any water-mediated hydrogen bond. However, the ligand could still engage the phosphotyrosine pocket in the same manner as before. In addition, the oxadiazole ring could still stack on top of the hydrophobic surface at the pY+2 position and directs the 2-naphthalene moiety deep into the pY+3 pocket. From these modeling efforts, it is also evident that the pY+3 pocket could not tolerate any ortho substitution pattern because of possible steric clashes with the protein surface. Further examination of these models also suggested a few other changes at the various positions of the oxadiazole scaffold. At the C-terminal ZAP, there is a rather large hydrophobic at the pY+1 position. A longer side chain at this position, such as the one deriving from L-homo-Phe, might be able to access this hydrophobic surface. At the N-terminal ZAP, if a hydroxymethyl group is used at the pY+1 position, there is a possibility for some additional water-mediated hydrogen bonding. Analogs deriving from L-homo-Phe (Table 6 , compounds 76a-c) and L-Ser (compounds 77a-c) were then made; and all of these were about two-fold more active than the corresponding analogs deriving from L-Ala. Note that even though the analogs deriving from L-homo-Phe were still selective over Syk, their selectivity was not as high as what had been observed previously with analogs deriving from L-Ala or L-Ser.
Additional modeling also suggested that an additional aromatic group at the N-acetyl portion of these 1,2,4-oxadiazole analogs could offer some additional contact with the Arg group of the protein. We then installed the phenyl acetyl N-cap onto a small number of analogs deriving from L-serine (Table 6 , compounds 78a-c). In most cases, we did observe a two-fold increase in binding affinity . Compound 78c was the most active one. It had an IC 50 of 1 µM against the tandem SH2 domains of ZAP-70. It had an unprecedented level of selectivity over the closely related tyrosine kinase Syk (>500-fold) and was also highly selective over Src and Grb2. In terms of potency, this compound was about 400-fold more potent than the native tetrapeptide. More significantly, when compared with the high-affinity ζ-1-ITAM peptide, compound 78c was just about one order of magnitude less potent. Compound 78c, as well as the entire series of 1,2,4-oxadiazole analogs, offers a very convincing argument that potent and selective ZAP-70 SH2 inhibitors could indeed be designed around a Fig. (5) . Compound 75e when docked into the active site at the C-terminal SH2 domain of ZAP-70. monodentate scaffold instead of the larger bidentate one found in the ζ-1-ITAM peptide.
of potent activity in a functional cellular assay would undoubtedly represent a significant a achievement in the area of SH2 research. Such a success would also allow SH2 domains to gain more acceptance as attractive therapeutic targets for a number of disease areas.
Preliminary gel shift studies using a protein construct having only the C-terminal SH2 domain have ruled out the possibility that these compounds are engaging only the N-terminal of ZAP-70. The current understanding is that these compounds are engaging at the minimum the C-terminal of ZAP-70, or perhaps even both SH2 domains. Further structural studies are needed in order to ascertain the exact binding mode of these compounds.
